Integrating rare genetic variants into pharmacogenetic drug response predictions
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Variability in genes implicated in drug pharmacokinetics or drug response can modulate treatment efficacy or predispose to adverse drug reactions. Besides common genetic polymorphisms, recent sequencing projects revealed a plethora of rare genetic variants in genes encoding proteins involved in drug metabolism, transport, and response. RESULTS: To understand the global importance of rare pharmacogenetic gene variants, we mapped the variability in 208 pharmacogenes by analyzing exome sequencing data from 60,706 unrelated individuals and estimated the importance of rare and common genetic variants using a computational prediction framework optimized for pharmacogenetic assessments. Our analyses reveal that rare pharmacogenetic variants were strongly enriched in mutations predicted to cause functional alterations. For more than half of the pharmacogenes, rare variants account for the entire genetic variability. Each individual harbored on average a total of 40.6 putatively functional variants, rare variants accounting for 10.8% of these. Overall, the contribution of rare variants was found to be highly gene- and drug-specific. Using warfarin, simvastatin, voriconazole, olanzapine, and irinotecan as examples, we conclude that rare genetic variants likely account for a substantial part of the unexplained inter-individual differences in drug metabolism phenotypes. CONCLUSIONS: Combined, our data reveal high gene and drug specificity in the contributions of rare variants. We provide a proof-of-concept on how this information can be utilized to pinpoint genes for which sequencing-based genotyping can add important information to predict drug response, which provides useful information for the design of clinical trials in drug development and the personalization of pharmacological treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716 · cited 1×
“Notably, genetic variability in non-coding regions has been demonstrated to have important influence on phenotypic traits [45].”
BackgroundSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“ADRs related to high-dose simvastatin therapy are strongly linked to the common (12.9% MAF) genetic variant rs4149056 in SLCO1B1 (encoding the transporter OATP1B1) with an odds ratio of 4.5 per copy of the risk allele [22].”
BackgroundInfluentialEvolution and functional impact of rare coding variation from deep sequencing of human exomes
Tennessen, J. A., Bigham, A. W., O’Connor, T. D., Fu, W., Kenny, E. E., Gravel, S., McGee, S., Do, R., Liu, X., Jun, G., et al. (2012) · Science · doi:10.1126/science.1219240 · Cited by 1,613 · cited 1×
“2b), consistent with previous reports [12, 14, 15].”
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people
Nelson, M. R., Wegmann, D., Ehm, M. G., Kessner, D., St. Jean, P., Verzilli, C., Shen, J., Tang, Z., Bacanu, S.-A., Fraser, D., et al. (2012) · Science · doi:10.1126/science.1217876 · Cited by 647
Cited by
Pharmacogenomics: current status and future perspectives
Pirmohamed, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00572-8 · Cited by 351
McInnes, G., Sharo, A. G., Koleske, M. L., Brown, J. E. H., Norstad, M., Adhikari, A. N., Wang, S., Brenner, S. E., Halpern, J., Koenig, B. A., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.03.003 · Cited by 86
“This can lead to health disparities based on a patient’s ancestry and is problematic for all individuals because rare variants are estimated to contribute to as much as 50% of interindividual variation in drug response.(12) IEMs encompass more than 1,000 genetic disorders, including organic acidemias, urea cycle defec…”
BackgroundA review on the recent applications of deep learning in predictive drug toxicological studies
Sinha, K., Ghosh, N., & Sil, P. C. (2023) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00375 · Cited by 64
Metadata
- Authors
- Ingelman-Sundberg, M., Mkrtchian, S., Zhou, Y., & Lauschke, V. M.
- Venue
- Human Genomics
- Published
- 2018-05-25
- Volume
- 12
- Issue
- 1
- Pages
- 26-26
- ISSN
- 1473-9542 (ISSN-L)
- 1479-7364
- OpenAlex
- W2804079128
- Cited by
- 215
- References
- 6
- FWCI
- 24.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrating rare genetic variants into pharmacogenetic drug response predictions. https://app.cochat.ai/papers/10.1186/s40246-018-0157-3
- The paper
- Ingelman-Sundberg, M., Mkrtchian, S., Zhou, Y., & Lauschke, V. M. (2018). Integrating rare genetic variants into pharmacogenetic drug response predictions. Human Genomics. https://doi.org/10.1186/s40246-018-0157-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.